PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
34.84%
EBIT growth of 34.84% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
34.84%
Operating income growth of 34.84% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
34.95%
Net income growth of 34.95% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
34.48%
EPS growth of 34.48% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
34.48%
Diluted EPS growth of 34.48% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
0.38%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.38%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-1204.92%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-1204.92%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.69%
OCF/share CAGR of 70.69% while Healthcare median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
70.69%
OCF/share CAGR of 70.69% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
70.69%
3Y OCF/share growth of 70.69% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
85.51%
Net income/share CAGR exceeding 1.5x Healthcare median of 18.61% over a decade. Joel Greenblatt might see a standout compounder of earnings.
85.51%
5Y net income/share CAGR > 1.5x Healthcare median of 18.20%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
85.51%
3Y net income/share CAGR of 85.51% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
-39.50%
Negative 10Y equity/share growth while Healthcare median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-39.50%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-39.50%
Negative 3Y equity/share growth while Healthcare median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.18%
AR shrinking while Healthcare median grows. Seth Klarman sees potential advantage unless it signals declining demand.
No Data
No Data available this quarter, please select a different quarter.
-10.91%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-7.36%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.85%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.